Durata Therapeutics

About:

Durata Therapeutics is a clinical, development-stage pharmaceutical company focused on the treatment of infectious diseases.

Website: http://www.duratatherapeutics.com

Top Investors: PDL Biopharma

Description:

Durata was created by a five-member venture capital syndicate to pursue late-stage clinical development of novel antibiotic programs. The acquisition was funded through a stock purchase by New Leaf Venture Partners, LLC, Domain Associates, LLC, Aisling Capital, Sofinnova Ventures Inc. and Canaan Partners. Durata is focused on Vicuron’s antibiotic drug candidate, dalbavancin. Its product portfolio also includes two preclinical antibiotic programs while Pfizer will retain the marketed anti-fungal agent, EraxisTM, which was formerly owned by Vicuron.